NASDAQ:FPRX
Delisted
Five Prime Therapeutics Stock News
$38.00
+0 (+0%)
At Close: May 27, 2022
4 Smaller, Cash-Rich Biotech Stocks That Could Be Safe Havens
03:49pm, Friday, 06'th Mar 2020
“A volatile, risk-off environment could make these relative outperformers,” writes Jeffries’ Michael Yee.
Five Prime Therapeutics (NASDAQ:FPRX) Raised to "Buy" at Zacks Investment Research
11:12am, Friday, 06'th Mar 2020
Zacks Investment Research upgraded shares of Five Prime Therapeutics (NASDAQ:FPRX) from a hold rating to a buy rating in a report released on Tuesday, Zacks.com reports. They currently have $4.50 pric
California Public Employees Retirement System Has $166,000 Stake in Five Prime Therapeutics Inc (NASDAQ:FPRX)
10:28am, Friday, 06'th Mar 2020
California Public Employees Retirement System lifted its position in shares of Five Prime Therapeutics Inc (NASDAQ:FPRX) by 108.7% during the fourth quarter, according to its most recent disclosure wi
Edited Transcript of MRK.DE earnings conference call or presentation 5-Mar-20 1:00pm GMT
09:52pm, Thursday, 05'th Mar 2020
Full Year 2019 Merck KGaA Earnings Call
Amunix Raises $73M to Bring Safer T Cell Engagers to Solid Tumors
06:33pm, Wednesday, 04'th Mar 2020
Cell therapies have helped treat some blood cancers, but toxic side effects are one limitation preventing their use in solid tumors. Amunix has, since its
Five Prime Therapeutics (NASDAQ:FPRX) Stock Rating Lowered by JPMorgan Chase & Co.
11:20am, Sunday, 01'st Mar 2020
Five Prime Therapeutics (NASDAQ:FPRX) was downgraded by stock analysts at JPMorgan Chase & Co. from a “neutral” rating to an “underweight” rating in a research report issued to clients and inv
US$8.00: That’s What Analysts Think Five Prime Therapeutics, Inc. Is Worth After Its Latest Results
02:20pm, Saturday, 29'th Feb 2020
Shareholders in Five Prime Therapeutics, Inc. (NASDAQ:FPRX) had a terrible week, as shares crashed 29% to US$3.82 in...
Five Prime Therapeutics (FPRX) Receives a Buy from Cowen & Co.
11:31am, Friday, 28'th Feb 2020
Cowen & Co. analyst Chris Shibutani maintained a Buy rating on Five Prime Therapeutics (FPRX) today. The company's shares closed last Monday at $4.32,
Five Prime Therapeutics (FPRX) Receives a Buy from Cowen & Co.
11:31am, Friday, 28'th Feb 2020
Cowen & Co. analyst Chris Shibutani maintained a Buy rating on Five Prime Therapeutics (FPRX – Research Report) today. The
Five Prime Therapeutics (NASDAQ:FPRX) Stock Price Down 10.6%
10:44am, Friday, 28'th Feb 2020
Five Prime Therapeutics Inc (NASDAQ:FPRX) shares fell 10.6% on Thursday . The stock traded as low as $4.27 and last traded at $4.32, 604,731 shares changed hands during trading. An increase of 27% fro
Five Prime Therapeutics, Inc. (FPRX) CEO William Ringo on Q4 2019 Results - Earnings Call Transcript
02:44am, Friday, 28'th Feb 2020
Start Time: 16:30 End Time: 17:16 Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Q4 2019 Earnings Conference Call February 27, 2020, 16:30 PM ET Company Participan
JP Morgan Downgrades Five Prime Therapeutics to Underweight
12:00am, Friday, 28'th Feb 2020Five Prime Therapeutics (FPRX) Reports Q4 Loss, Misses Revenue Estimates
10:45pm, Thursday, 27'th Feb 2020
Five Prime Therapeutics (FPRX) delivered earnings and revenue surprises of 8.25% and -20.66%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the st
Five Prime Therapeutics (FPRX) Reports Q4 Loss, Misses Revenue Estimates
10:45pm, Thursday, 27'th Feb 2020
Five Prime Therapeutics (FPRX) delivered earnings and revenue surprises of 8.25% and -20.66%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the st
